Literature DB >> 15042392

The upregulation of endothelial nitric oxide synthase and urotensin-II is associated with pulmonary hypertension and vascular diseases in rats produced by aortocaval shunting.

Jianguang Qi1, Junbao Du, Xiuying Tang, Jian Li, Bing Wei, Chaoshu Tang.   

Abstract

The mechanism of pulmonary vascular structural remodeling and pulmonary hypertension induced by high pulmonary blood flow is still unclear. Nitric oxide (NO) and carbon monoxide (CO) are two gaseous molecules recently discovered; both can induce the relaxation of blood vessels and inhibit the proliferation of vascular smooth muscle cells. More recently, urotensin-II (U-II) has been considered as the most potent mammalian vasoconstrictor identified so far, which can promote the proliferation of vascular smooth muscle cells. The aim of this study was to investigate the alteration of micro- and ultrapathologic structure, gaseous molecules, and U-II in rats with pulmonary hypertension induced by increased pulmonary blood flow. Aortocaval shunting was produced in rats. After 11-weeks of shunting, pulmonary artery mean pressure (PAMP) was measured. Pulmonary vascular micro- and ultrastructure was examined. Meanwhile, the concentration of plasma NO and CO was measured by spectrophotometry. The expression of endothelial nitric oxide synthase (eNOS), heme oxygenase-1 (HO-1), and U-II by pulmonary arteries was detected by immunohistochemistry. The results showed that PAMP was significantly elevated after 11 weeks of aortocaval shunting (2.99 +/- 0.35 kPa vs 2.09 +/- 0.38 kPa, P << 0.01). Muscularization of small pulmonary vessels and relative medial thickness of pulmonary arteries were obviously increased in shunt rats compared with controls. Ultrastructural changes were found in intrapulmonary arteries of shunt rats. Meanwhile, plasma NO concentration was increased and eNOS expression by pulmonary artery endothelial cells was significantly augmented in rats of the shunting group, but there was no significant difference in plasma CO level and HO-1 expression by pulmonary artery smooth muscle cells between shunting and sham groups. Urotensin-II expression by pulmonary artery endothelial cells and smooth muscle cells was significantly strengthened in shunt rats compared with sham rats. The results suggest that pulmonary vascular structural remodeling is an important pathologic basis of pulmonary hypertension induced by a left-to-right shunt. Upregulation of U-II might play an important role in the development of high pulmonary blood flow-induced pulmonary hypertension. Nitric oxide, as a modifying factor, might be involved in the regulation of pulmonary vascular structural remodeling.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15042392     DOI: 10.1007/s00380-003-0739-3

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  11 in total

1.  Urotensin-II in systemic sclerosis: a new peptide in pathogenesis.

Authors:  Yavuz Pehlivan; Ahmet Mesut Onat; Gazi Comez; Taner Babacan
Journal:  Clin Rheumatol       Date:  2011-01-28       Impact factor: 2.980

Review 2.  The dynamic regulation of microcirculatory conduit function: features relevant to transfusion medicine.

Authors:  Arif Somani; Marie E Steiner; Robert P Hebbel
Journal:  Transfus Apher Sci       Date:  2010-06-26       Impact factor: 1.764

3.  Palosuran treatment effective as bosentan in the treatment model of pulmonary arterial hypertension.

Authors:  Yavuz Pehlivan; Recep Dokuyucu; Tuncer Demir; Davut Sinan Kaplan; Ibrahim Koc; Mustafa Orkmez; Ibrahim Halil Turkbeyler; Ali Osman Ceribasi; Ediz Tutar; Seyithan Taysi; Bunyamin Kisacik; Ahmet Mesut Onat
Journal:  Inflammation       Date:  2014-08       Impact factor: 4.092

4.  Induced Pluripotent Stem Cell Model of Pulmonary Arterial Hypertension Reveals Novel Gene Expression and Patient Specificity.

Authors:  Silin Sa; Mingxia Gu; James Chappell; Ning-Yi Shao; Mohamed Ameen; Kathryn A T Elliott; Dan Li; Fabian Grubert; Caiyun G Li; Shalina Taylor; Aiqin Cao; Yu Ma; Ryan Fong; Long Nguyen; Joseph C Wu; Michael P Snyder; Marlene Rabinovitch
Journal:  Am J Respir Crit Care Med       Date:  2017-04-01       Impact factor: 21.405

5.  Serum levels of angiopoietin-1 in patients with pulmonary hypertension due to mitral stenosis.

Authors:  Hekim Karapınar; Ozlem Esen; Yunus Emiroğlu; Mustafa Akçakoyun; Selçuk Pala; Ramazan Kargın; Akın Izgi; Cevat Kirma; Ali Metin Esen
Journal:  Heart Vessels       Date:  2010-12-08       Impact factor: 2.037

Review 6.  Urotensin-II and cardiovascular diseases.

Authors:  Nicolas Bousette; Adel Giaid
Journal:  Curr Hypertens Rep       Date:  2006-12       Impact factor: 5.369

7.  Urotensin inhibition with palosuran could be a promising alternative in pulmonary arterial hypertension.

Authors:  Ahmet Mesut Onat; Yavuz Pehlivan; Ibrahim Halil Turkbeyler; Tuncer Demir; Davut Sinan Kaplan; Ali Osman Ceribasi; Mustafa Orkmez; Ediz Tutar; Seyithan Taysi; Mehmet Sayarlioglu; Bunyamin Kisacik
Journal:  Inflammation       Date:  2013-04       Impact factor: 4.092

Review 8.  Pulmonary vascular disease related to hemodynamic stress in the pulmonary circulation.

Authors:  Stephen Y Chan; Joseph Loscalzo
Journal:  Compr Physiol       Date:  2011-01       Impact factor: 9.090

9.  Effects of Urotensin II Receptor Antagonist, GSK1440115, in Asthma.

Authors:  Alison Portnoy; Sanjay Kumar; David J Behm; Kelly M Mahar; Robert B Noble; John P Throup; Steven F Russ
Journal:  Front Pharmacol       Date:  2013-04-29       Impact factor: 5.810

10.  Urotensin-II: More Than a Mediator for Kidney.

Authors:  Ayşe Balat; Mithat Büyükçelik
Journal:  Int J Nephrol       Date:  2012-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.